Amgen vs Biogen
AMGN and BIIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMGN and BIIB compare
Amgen is the larger company, worth 6.7 times as much as Biogen ($248B against $37.1B).
On earnings, Amgen is cheaper: it trades at 26.5× trailing earnings, against 107× for Biogen.
Amgen grew revenue faster over the last twelve months (8.2% versus 2.3% for Biogen).
Amgen keeps more of each dollar of sales as profit, with a net margin of 24.1% compared with 3.4% at Biogen.
Amgen pays a dividend yielding 2.2%; Biogen does not pay one.
Amgen scores higher on the StockData Score (17 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMGN | BIIB |
|---|---|---|
| Size and price | ||
| Market cap | $248B | $37.1B |
| Share price | $457.93 | $250.79 |
| Change, 1 year | 36.0% | 49.7% |
| Change, 5 years | 128% | 3.2% |
| Beta (5Y) | 0.32 | 0.14 |
| Employees | 32K | 7,500 |
| StockData Score | ||
| Total score | 17 (better) | 4 |
| Valuation score | 0 | 1 (better) |
| Growth score | 5 (better) | 0 |
| Performance score | 6 (better) | 1 |
| Health score | 2 | 2 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 26.5× (better) | 107× |
| P/S | 6.4× | 3.6× (better) |
| P/B | 17.3× | – |
| EV/EBITDA | 18.8× (better) | 21.9× |
| P/FCF | 25.8× | 17.9× (better) |
| PEG | 4.81 | – |
| FCF yield | 3.9% | 5.6% (better) |
| Fair value | $364.40 | $160.54 |
| Margin of safety | −25.7% (better) | −56.2% |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | 2.3% |
| Revenue growth, 5Y average | 7.6% (better) | −6.0% |
| Net income growth (TTM) | 34.1% (better) | −78.4% |
| EPS growth (TTM) | 33.3% (better) | −78.7% |
| EPS growth, 5Y average | 2.9% (better) | −18.7% |
| Profitability | ||
| Gross margin | 70.9% | 74.0% (better) |
| Operating margin | 32.4% | – |
| Net margin | 24.1% (better) | 3.4% |
| FCF margin | 24.6% (better) | 20.1% |
| Return on equity | 78.4% | – |
| Return on invested capital | 19.5% | – |
| Financial health | ||
| Debt / equity | 3.76 | – |
| Net debt / EBITDA | 2.67 | – |
| Interest coverage | 4.8× | – |
| Current ratio | 1.48 | 1.95 (better) |
| Altman Z-score | 2.51 | 3.07 (better) |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 2.2% | – |
| Payout ratio | 57.1% | – |
| Years of dividend growth | 9 | – |
| Dividend growth, 5Y average | 8.0% | – |
| Shareholder yield | 2.2% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 82.7% | 96.2% |
| Held by insiders | 0.21% | 0.21% |
| Insider net buying, 12 months | −$25.7M | −$905K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.3% | 3.7% |
Go deeper
- AMGN stock overview
- AMGN income statement
- AMGN valuation and score
- BIIB stock overview
- BIIB income statement
- BIIB valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.